‘Mr. Vedam, where were you born?’: A man who spent 43 years in prison before his conviction was thrown out now faces deportation

GoDaddy's CEO, Aman Bhutani, has announced an ambitious plan to transform the company through generative AI tools. By the end of this year, GoDaddy aims for 70% of its code to be AI-generated, showcasing a significant shift in how the company operates. This move not only highlights the growing importance of AI in the tech industry but also positions GoDaddy as a leader in innovation, potentially enhancing its services and customer experience.

DTE Energy has released its Q3 financial statements for DTE Gas Company on its official website. This update is significant as it provides stakeholders with insights into the company's financial health and operational performance during the third quarter, allowing investors and analysts to assess its progress and future outlook.

Bulova has launched an eye-catching dive watch priced at just $280, making it an attractive option for watch enthusiasts. This watch not only boasts a stylish design but also features a secret element on the back, adding a unique twist that sets it apart from typical dive watches. This release is significant as it combines affordability with innovative design, appealing to both casual wearers and serious collectors.

GeneDx Holdings' CFO, Feeley, has sold $52,977 worth of stock, which is a routine part of managing personal investments. Such transactions can often indicate the executive's confidence in the company's future or personal financial planning. While this sale might raise some eyebrows, it's important to remember that executives frequently buy and sell shares for various reasons.

In a significant move, a director at BridgeBio Pharma has sold $13.2 million worth of BBIO stock, raising concerns among investors about the company's future. Such large stock sales by insiders can often signal a lack of confidence in the company's performance, leading to speculation and potential volatility in the stock price. This development is particularly noteworthy as it comes at a time when the biotech sector is facing various challenges, making it crucial for stakeholders to closely monitor the situation.

Core Scientific shareholders have voted against the proposed merger with CoreWeave, leading to the termination of the agreement. This decision reflects the shareholders' concerns about the potential benefits of the merger and raises questions about the future direction of Core Scientific. The rejection of this merger could impact the company's growth strategy and its competitive position in the market.